Xing Luo PhD , Ji Li PhD , Yuwu Chen MD , Xiuzhu Weng MD , Xiaoyi Bao PhD , Xiaoxuan Bai MD , Ying Lv PhD , Shan Zhang PhD , Xinxin Zhu MD , Biyi Xu MD , Chen Zhao MD , Ming Zeng MD , Tianyu Wu MD , Qianhui Sun MD , Shengfang Wang PhD , Minghao Liu MD , Thomas Johnson PhD , Stephen J. White PhD , Peter Libby MD , Sining Hu PhD , Haibo Jia PhD
{"title":"香烟焦油通过CAMKII/Drp1/mtDNA促进ECs热亡","authors":"Xing Luo PhD , Ji Li PhD , Yuwu Chen MD , Xiuzhu Weng MD , Xiaoyi Bao PhD , Xiaoxuan Bai MD , Ying Lv PhD , Shan Zhang PhD , Xinxin Zhu MD , Biyi Xu MD , Chen Zhao MD , Ming Zeng MD , Tianyu Wu MD , Qianhui Sun MD , Shengfang Wang PhD , Minghao Liu MD , Thomas Johnson PhD , Stephen J. White PhD , Peter Libby MD , Sining Hu PhD , Haibo Jia PhD","doi":"10.1016/j.jacbts.2025.03.015","DOIUrl":null,"url":null,"abstract":"<div><div>Smoking is the only cardiovascular risk factor for plaque erosion. We found cigarette tar resulted in erosion-like lesion development in apolipoprotein E<sup>−/−</sup> mice, with mural thrombosis, discontinuous endothelium, platelet activation, smooth muscle cell proliferation, and hyaluronic acid accumulation in the aorta. Single-cell transcriptomics revealed that genes relating to pyroptosis, platelet activation, and leukocytes adhesion were significantly increased in an endothelial cell subset. Rescue assays indicated cigarette tar caused human coronary artery endothelial cell pyroptosis by enhanced calcium–calmodulin-dependent protein kinase II / dynamin-related protein 1–mediated mitochondrial fission and mitochondrial DNA release via activating Ca<sup>2+</sup> signaling. Inhibition of endothelial cell pyroptosis may be a novel therapeutic strategy to reduce plaque erosion.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"10 8","pages":"Article 101283"},"PeriodicalIF":8.4000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cigarette Tar Enhanced ECs Pyroptosis via CAMKII/Drp1/mtDNA\",\"authors\":\"Xing Luo PhD , Ji Li PhD , Yuwu Chen MD , Xiuzhu Weng MD , Xiaoyi Bao PhD , Xiaoxuan Bai MD , Ying Lv PhD , Shan Zhang PhD , Xinxin Zhu MD , Biyi Xu MD , Chen Zhao MD , Ming Zeng MD , Tianyu Wu MD , Qianhui Sun MD , Shengfang Wang PhD , Minghao Liu MD , Thomas Johnson PhD , Stephen J. White PhD , Peter Libby MD , Sining Hu PhD , Haibo Jia PhD\",\"doi\":\"10.1016/j.jacbts.2025.03.015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Smoking is the only cardiovascular risk factor for plaque erosion. We found cigarette tar resulted in erosion-like lesion development in apolipoprotein E<sup>−/−</sup> mice, with mural thrombosis, discontinuous endothelium, platelet activation, smooth muscle cell proliferation, and hyaluronic acid accumulation in the aorta. Single-cell transcriptomics revealed that genes relating to pyroptosis, platelet activation, and leukocytes adhesion were significantly increased in an endothelial cell subset. Rescue assays indicated cigarette tar caused human coronary artery endothelial cell pyroptosis by enhanced calcium–calmodulin-dependent protein kinase II / dynamin-related protein 1–mediated mitochondrial fission and mitochondrial DNA release via activating Ca<sup>2+</sup> signaling. Inhibition of endothelial cell pyroptosis may be a novel therapeutic strategy to reduce plaque erosion.</div></div>\",\"PeriodicalId\":14831,\"journal\":{\"name\":\"JACC: Basic to Translational Science\",\"volume\":\"10 8\",\"pages\":\"Article 101283\"},\"PeriodicalIF\":8.4000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JACC: Basic to Translational Science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2452302X25001676\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452302X25001676","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Cigarette Tar Enhanced ECs Pyroptosis via CAMKII/Drp1/mtDNA
Smoking is the only cardiovascular risk factor for plaque erosion. We found cigarette tar resulted in erosion-like lesion development in apolipoprotein E−/− mice, with mural thrombosis, discontinuous endothelium, platelet activation, smooth muscle cell proliferation, and hyaluronic acid accumulation in the aorta. Single-cell transcriptomics revealed that genes relating to pyroptosis, platelet activation, and leukocytes adhesion were significantly increased in an endothelial cell subset. Rescue assays indicated cigarette tar caused human coronary artery endothelial cell pyroptosis by enhanced calcium–calmodulin-dependent protein kinase II / dynamin-related protein 1–mediated mitochondrial fission and mitochondrial DNA release via activating Ca2+ signaling. Inhibition of endothelial cell pyroptosis may be a novel therapeutic strategy to reduce plaque erosion.
期刊介绍:
JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.